Skip to main content
Caplight Logo









Lophora

Lophora

Private
CharlottenlundHealthcare & Life Scienceshttps://www.lophora.com/

Last Round

VC Round

Jan 15, 2025

Total Funding Raised

$2.2M

Company Overview

Lophora is a clinical-stage CNS therapeutics company developing differentiated, next-generation neuroactive medicines designed to induce neuroplasticity and address significant unmet needs in neuropsychiatry.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Mental Health, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyCNS disordersdrug discoverypsychedelic medicine5-HT2A receptor agonistneuroplasticityclinical-stage biotechneuropsychiatric disorderssmall-molecule therapeuticsmental healthnext-gen psychedelicsnon-hallucinogenicclinical trialsbiotech licensingnovel chemical entities

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Lophora Comparables

Compare Lophora with similar companies based on industry and business-model similarity.

Lophora comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Delix Therapeutics
89%
Xylo Bio
83%
Reunion Neuroscience Inc.
83%

Lophora Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJan 15, 2025
VC RoundAug 24, 2023
VC RoundMar 2, 2021
GrantMar 2, 2021
Convertible DebtApr 3, 2020

Key People

Founding team and executive leadership

Emil Marcher-Rørsted

Chief Research Officer (CRO), Co-Founder

Founding Team

Bo Tandrup

Co-founder & CEO

Founding Team

Lophora Investors

Notable investors and investment history

Lophora investors
InvestorRounds
Innovation Fund DenmarkGrant
Novo Nordisk FoundationConvertible Debt
The Export and Investment Fund of DenmarkVC Round
BioInnovation InstituteConvertible Debt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 6, 2026

    Monthly visitors grew 247% MoM, from 420 to 1.5K.

  • Jan 14, 2025

    Monthly visitors grew 247% MoM to 594.

Lophora Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Lophora Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Lophora's valuation, stock price, and market status.

Firmographic Details

HeadquartersCharlottenlund
Employee Range8
Year Founded2018
Last FundingJan 15, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?